At present, RainMed Medical has successively established strategic cooperative relations with top enterprises such as Ping An Capital, GE Medical China, China Resources Medical Devices, Jointown Medical Devices, Hanxiputai and so on. Through a series of strategic cooperation, RainMed Medical builds a high-end circle of friends in the field of accurate diagnosis and treatment, jointly promotes the capital operation, technology innovation, marketing, channel building, and accelerates the ecological building and strategic implementation of vascular interventional surgery robots to better empower clinicians and benefit the patients with cardiovascular disease at home and abroad.

RainMed Medical is committed to becoming the world's leading panvascular interventional robotics company. Currently, it focuses on the design, development and commercialization of coronary artery functional products, and creates a series of epoch-making functional diagnostic and treatment products. In terms of scientific research, the company continues to promote scientific cooperation with top medical centers at home and abroad and has published more than 20 important clinical research articles in top journals. In terms of capital operation, the company completed two rounds of financing efficiently within one year, paving the way to access to the capital market. In terms of marketing, the company has quickly realized the commercialization of precision diagnosis and treatment technology. The products have been used in nearly a thousand hospitals and fully entered the strategic landing stage of vascular interventional surgery robot. In terms of production quality control, the company continues to increase investment in production capacity and equipment upgrading, and establishes industry-leading production system and supply chain system. The outstanding achievements made by RainMed Medical and the great prospect of building the world's leading vascular interventional surgery robotics company have also attracted the extensive attention of the industry's famous investment institutions, technology companies, logistics platforms and hospital groups, and promoted the establishment of close strategic cooperation.

The rapid growth of RainMed has attracted extensive attention from investment institutions. Recently, Ping An Capital invested tens of millions of dollars to lead the series D financing of RainMed Medical, and foreign well-known asset management institutions followed the investment. After this round of financing, RainMed's valuation has been greatly improved and all work has been accelerated. Ping An Capital highly recognizes the advanced product concept, strong scientific research strength, strong management level and efficient execution ability of RainMed Medical team, and continues to expand the scope of cooperation with RainMed Medical. Ping An Capital has signed a strategic cooperation agreement to jointly promote cooperation in the fields of scientific and technological innovation, capital operation and ESG. Dong Liu, chairman of Ping An Capital, praised RainMed medical's current achievements and expressed expectations for the follow-up cooperation. He said: "As the core private equity platform of Ping An Group, Ping An Capital has the responsibility and ability to promote RainMed Medical to accelerate the improvement of the commercialization network and accelerate the application of the RainMed's products in clinical practice. In the future, Ping An Capital will continue to help RainMed Medical to develop revolutionary diagnosis and treatment products, implement vascular interventional surgery robot strategy, and benefit domestic and overseas patients." 

The strategic cooperation between GE Healthcare China and RainMed Medical organically combines imaging diagnosis and functional diagnosis of coronary intervention to create more accurate coronary intervention, so as to better serve patients with cardiovascular disease and coronary interventional doctors. Wei Chen, the leader of China Resources Medical Business Group, clearly stated that China Resources attaches great importance to medical devices, and the field of cardiovascular and cerebrovascular devices is one of the key development directions of China Resources Medical Devices. The cooperation with RainMed Medical will bring global leading diagnostic and treatment products to the platform. Xiong Fu, vice chairman of Jointown Pharmaceutical Group, also said “The cooperation between Jointown Medical and RainMed Medical makes me feel secure and reliable. I hope that in the future cooperation, both parties can make use of their own resource advantages, continue to innovate, dig deep value, and build the most professional cardiovascular medical device supply chain in China." In addition to China Resources Medical Devices, Jointown Medical Devices and other medical distribution and platform companies, domestic cardiovascular hospitals also attach great importance to the application of precise cardiovascular disease assessment, and actively seek leading automatic precision diagnosis and treatment technology. As the first Chinese enterprise to gain market access in China and the EU, the clinical and scientific value of products developed by RainMed Medical Institute has been unanimously affirmed by experts and scholars at home and abroad. Hanxiputai, a leading cardiovascular hospital investment management institution in China, is committed to creating a high-quality cardiovascular health medical service platform. The cooperation with RainMed Medical will greatly enhance the comprehensive competitiveness of Hanxiputai. Jiansheng Hao, chairman of Hanxiputai, is full of expectations for this cooperation. He hopes that both sides will carry out comprehensive cooperation in clinical research, health management and other fields in the future to build a perfect medical service system.

With the growth of the company's comprehensive strength, RainMed Medical has gradually established close cooperation with the leading enterprises in the fields of health investment, medical technology, equipment circulation, professional hospitals and so on. In the future, with the help of the high-end "Circle of Friends" of precision diagnosis and treatment with strategic partners such as Ping An Capital, GE Medical China and China Resources Medical Equipment, RainMed Medical's vascular interventional surgery robot strategy will be fully accelerated in capital operation, pipeline research and development, marketing and other aspects.

In the future, RainMed Medical will continue to adhere to independent innovation, focus on research and development, continue to develop epoch-making advanced vascular diagnosis and treatment products such as vascular interventional surgery robot, promote the implementation of cutting-edge diagnosis and treatment technology, and contribute to the accelerated realization of the strategic goal of Healthy China!